• <blockquote id="qosqq"></blockquote>
  • <noscript id="qosqq"></noscript>

    <small id="qosqq"><dd id="qosqq"></dd></small>
    1. Pipeline

      Gilead’s research and development program identifies and evaluates investigational compounds that show potential to advance the treatment of life-threatening diseases in areas of unmet medical need.

      Pipeline

      HIV / AIDS

      Gilead is committed to pursuing innovation in HIV across the spectrum of care. We are working to address remaining needs in both prevention and treatment. And, we are focused on discovery research that could potentially, one day, lead to a cure.

      The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

      • Emtricitabine and tenofovir alafenamide

        Potential Indication: PrEP

        Phase 1
        Phase 2
        Phase 3
      • GS-6207 (Capsid Inhibitor)

        Potential Indication: HIV/AIDS

        Phase 1
        Phase 2
        Phase 3
      • Vesatolimod (TLR-7 agonist)

        Potential Indication: HIV/AIDS

        Phase 1
        Phase 2
        Phase 3
      • Elipovimab (bNab)

        Potential Indication: HIV/AIDS

        Phase 1
        Phase 2
        Phase 3

      Liver Diseases

      Gilead’s liver disease research focuses on investigating medicines for patients with advanced fibrosis due to nonalcoholic steatohepatitis (NASH) and for potentially curing patients chronically infected with the hepatitis B virus (HBV).

      The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

      • Cilofexor (FXR agonist)

        Potential Indication: NASH

        Phase 1
        Phase 2
        Phase 3
      • Cilofexor (FXR agonist)

        Potential Indication: Primary Biliary Cirrhosis

        Phase 1
        Phase 2
        Phase 3
      • Cilofexor (FXR agonist)

        Potential Indication: Primary Sclerosing Cholangitis

        Phase 1
        Phase 2
        Phase 3
      • Firsocostat (ACC Inhibitor)

        Potential Indication: NASH

        Phase 1
        Phase 2
        Phase 3
      • Selgantolimod (TLR-8 agonist)

        Potential Indication: HBV

        Phase 1
        Phase 2
        Phase 3
      • GS-4224 (PD-L1 Inhibitor)

        Potential Indication: HBV

        Phase 1
        Phase 2
        Phase 3

      Hematology / Oncology

      Gilead is advancing a pipeline of cancer therapies in the areas of cell therapy, immuno-oncology and targeted therapies. Following the 2017 acquisition of Kite Pharma, Inc., our leading cell therapy pipeline now includes investigational cell therapies and next-generation technologies for a range of hematologic malignancies and solid tumors.

      The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

      • Axicabtagene ciloleucel

        Trial: ZUMA-5 Potential Indication: Indolent NHL

        Phase 1
        Phase 2
        Phase 3
      • Axicabtagene ciloleucel

        Trial: ZUMA-6 Potential Indication: DLBCL (+PD-L1 mAb)

        Phase 1
        Phase 2
        Phase 3
      • Axicabtagene ciloleucel

        Trial: ZUMA-7 Potential Indication: 2nd line DLBCL

        Phase 1
        Phase 2
        Phase 3
      • Axicabtagene ciloleucel

        Trial: ZUMA-11, Potential Indication: DLBCL (+4-1BB)

        Phase 1
        Phase 2
        Phase 3
      • Axicabtagene ciloeucel

        Trial: ZUMA-12 Potential Indication: 1st line DLBCL

        Phase 1
        Phase 2
        Phase 3
      • Axicabtagene ciloleucel

        Trial: ZUMA-14 Potential Indication: DLBCL (+rituximab or lenalidomide)

        Phase 1
        Phase 2
        Phase 3
      • KTE-X19

        Trial: ZUMA-2 Potential Indication: MCL

        Phase 1
        Phase 2
        Phase 3
      • KTE-X19

        Trial: ZUMA-3 Potential Indication: Adult ALL

        Phase 1
        Phase 2
        Phase 3
      • KTE-X19

        Trial: ZUMA-4 Potential Indication: Pediatric ALL

        Phase 1
        Phase 2
        Phase 3
      • KTE-X19

        Trial: ZUMA-8 Potential Indication: CLL

        Phase 1
        Phase 2
        Phase 3
      • KITE-718 (MAGE A3/A6)

        Potential Indication: Solid Tumor

        Phase 1
        Phase 2
        Phase 3
      • KITE-439 (HPV E7)

        Potential Indication: Solid Tumor

        Phase 1
        Phase 2
        Phase 3
      • GS-1423 (bi-specific antibody)

        Potential Indication: Solid Tumor

        Phase 1
        Phase 2
        Phase 3
      • GS-4224 (oral PD-L1 inhibitor)

        Potential Indication: Solid Tumor

        Phase 1
        Phase 2
        Phase 3

      Inflammation / Respiratory

      Gilead is advancing a pipeline of novel investigational agents for inflammatory diseases, addressing multiple targets with potential application across a broad range of disorders.

      The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

      • Filgotinib (JAK1 inhibitor)

        Potential Indication: Rheumatoid Arthritis

        Phase 1
        Phase 2
        Phase 3
      • Filgotinib (JAK1 inhibitor)

        Potential Indication: Crohn's Disease

        Phase 1
        Phase 2
        Phase 3
      • Filgotinib (JAK1 inhibitor)

        Potential Indication: Ulcerative Colitis

        Phase 1
        Phase 2
        Phase 3
      • Filgotinib (JAK-1 inhibitor)

        Potential Indication: Psoriatic Arthritis

        Phase 1
        Phase 2
        Phase 3
      • Filgotinib (JAK1 inhibitor)

        Potential Indication: Inflammatory Diseases

        Phase 1
        Phase 2
        Phase 3
      • Filgotinib (JAK-1 inhibitor)

        Potential Indication: Ankylosing Spondylitis

        Phase 1
        Phase 2
        Phase 3
      • GS-9876 (Syk inhibitor)

        Potential Indication: Sjogren’s Syndrome

        Phase 1
        Phase 2
        Phase 3
      • GS-9876 (Syk inhibitor)

        Potential Indication: Lupus

        Phase 1
        Phase 2
        Phase 3
      • GS-4875 (TPL2 inhibitor)

        Potential Indication: Ulcerative Colitis

        Phase 1
        Phase 2
        Phase 3
      • GLPG-1690

        Potential Indication: Idiopathic Pulmonary Fibrosis

        Phase 1
        Phase 2
        Phase 3
      • GLPG-1690

        Potential Indication: Systemic Sclerosis

        Phase 1
        Phase 2
        Phase 3
      • Selonsertib (ASK-1 inhibitor)

        Potential Indication: DKD

        Phase 1
        Phase 2
        Phase 3

      Other

      Gilead is collaborating with U.S. Department of Defense, Centers for Disease Control and Prevention, and National Institutes of Health as well as multiple academic institutions to discover and develop novel antivirals for highly pathogenic infections and neglected/emerging viral diseases, including Ebola.

      The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

      • Remdesivir (GS-5734, Nuc inhibitor)

        Potential Indication: Ebola Virus Infection

        Phase 1
        Phase 2
        Phase 3

      Some of the content on this page is not intended for users outside the US.

      狼天天狼天天香蕉免费